JP6925344B2 - 細菌感染症の治療に有用な双性イオンプロパルギル結合抗葉酸剤 - Google Patents

細菌感染症の治療に有用な双性イオンプロパルギル結合抗葉酸剤 Download PDF

Info

Publication number
JP6925344B2
JP6925344B2 JP2018535383A JP2018535383A JP6925344B2 JP 6925344 B2 JP6925344 B2 JP 6925344B2 JP 2018535383 A JP2018535383 A JP 2018535383A JP 2018535383 A JP2018535383 A JP 2018535383A JP 6925344 B2 JP6925344 B2 JP 6925344B2
Authority
JP
Japan
Prior art keywords
compound
salt
compounds
dhfr
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018535383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504834A5 (enExample
JP2019504834A (ja
Inventor
デニス ライト
デニス ライト
エイミー シー アンダーソン
エイミー シー アンダーソン
エリック スコッケラ
エリック スコッケラ
ダヤナン ナレンドラン ガミューディプーンディ
ダヤナン ナレンドラン ガミューディプーンディ
サントシュ ケシペディー
サントシュ ケシペディー
ステファニー リーブ
ステファニー リーブ
マイケル エヌ ロンバード
マイケル エヌ ロンバード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Connecticut
Original Assignee
University of Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Connecticut filed Critical University of Connecticut
Publication of JP2019504834A publication Critical patent/JP2019504834A/ja
Publication of JP2019504834A5 publication Critical patent/JP2019504834A5/ja
Application granted granted Critical
Publication of JP6925344B2 publication Critical patent/JP6925344B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018535383A 2016-01-08 2017-01-09 細菌感染症の治療に有用な双性イオンプロパルギル結合抗葉酸剤 Active JP6925344B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276494P 2016-01-08 2016-01-08
US62/276,494 2016-01-08
PCT/US2017/012702 WO2017120575A1 (en) 2016-01-08 2017-01-09 Zwitterionic propargyl-linked antifolates useful for treating bacterial infections

Publications (3)

Publication Number Publication Date
JP2019504834A JP2019504834A (ja) 2019-02-21
JP2019504834A5 JP2019504834A5 (enExample) 2020-02-20
JP6925344B2 true JP6925344B2 (ja) 2021-08-25

Family

ID=57868417

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018535383A Active JP6925344B2 (ja) 2016-01-08 2017-01-09 細菌感染症の治療に有用な双性イオンプロパルギル結合抗葉酸剤

Country Status (5)

Country Link
US (1) US10870625B2 (enExample)
EP (1) EP3400222B1 (enExample)
JP (1) JP6925344B2 (enExample)
CN (1) CN109071511B (enExample)
WO (1) WO2017120575A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110590767B (zh) * 2019-08-29 2021-10-08 南方科技大学 一种合成amg837的方法
CN111848430B (zh) * 2020-07-22 2022-12-09 马鞍山诺恩特医药科技有限公司 2-([1,1’-联苯]-4-基)-2-甘氨酸类化合物的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853228B2 (en) * 2007-06-04 2014-10-07 University Of Connecticut Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase
US8426432B2 (en) 2007-06-04 2013-04-23 University Of Connecticut Inhibitors of dihydrofolate reductase with antibacterial antiprotozoal, antifungal and anticancer properties
US8767716B2 (en) * 2011-09-19 2014-07-01 Vonage Network, Llc Systems and methods of routing IP telephony data packet communications
US9382213B2 (en) 2014-02-12 2016-07-05 Promiliad Biopharma Inc. Heterocyclic and cyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase

Also Published As

Publication number Publication date
EP3400222B1 (en) 2021-07-14
CN109071511B (zh) 2022-06-07
US10870625B2 (en) 2020-12-22
EP3400222A1 (en) 2018-11-14
US20190002413A1 (en) 2019-01-03
WO2017120575A1 (en) 2017-07-13
CN109071511A (zh) 2018-12-21
JP2019504834A (ja) 2019-02-21

Similar Documents

Publication Publication Date Title
US20250388562A1 (en) Small molecule degraders of helios and methods of use
US10647700B2 (en) EZH2 inhibitor and use thereof
RU2662436C2 (ru) Содержащие заместители бензольные соединения
US9334527B2 (en) Inhibitors of human EZH2, and methods of use thereof
US9187474B2 (en) Raf inhibitor compounds
US8318720B2 (en) Acrylamide derivatives as Fab I inhibitors
US9643933B2 (en) Compounds useful as antibiotic tolerance inhibitors
US9598407B2 (en) Antibacterial piperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
AU2013232229A1 (en) Inhibitors of human EZH2, and methods of use thereof
CN105473578A (zh) 用于治疗抗药性和持续性结核病的化合物
CA3174321A1 (en) Indazole derivatives as inhibitors of sarm1
CN102388053A (zh) 作为抗感染剂的羟基噻吩并喹诺酮类及相关化合物
CN106029104A (zh) 包含锌螯合部分的金属-β-内酰胺酶(MBL)抑制剂
CN109952297A (zh) 化合物
TWI799814B (zh) 噁唑啶酮化合物及其做為抗菌劑之使用方法
BG108548A (bg) Хетероциклични съединения и използването им като d-аланил-d-аланин лигазни инхибитори
TW201625610A (zh) 萘啶二酮（ｎａｐｈｔｈｙｒｉｄｉｎｅｄｉｏｎｅ）衍生物
AU2010275375B2 (en) Spectinamides as anti-tuberculosis agents
US9079870B2 (en) Thiol mediated/activated prodrugs of sulfur dioxide (SO2) having anti-bacterial activity
US10870625B2 (en) Zwitterionic propargyl-linked antifolates useful for treating bacterial infections
US20240307369A1 (en) Exo VII Inhibitor and Quinolone Antibiotic Combination Useful for Treating Bacterial Infection
WO2020257734A1 (en) Compounds, compositions, and methods for treating, ameliorating, or preventing bacterial infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210419

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210803

R150 Certificate of patent or registration of utility model

Ref document number: 6925344

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250